Astria Therapeutics (ATXS) Share-based Compensation: 2013-2024
Historic Share-based Compensation for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to $13.0 million.
- Astria Therapeutics' Share-based Compensation fell 33.87% to $285,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $1.5 million, marking a year-over-year decrease of 14.67%. This contributed to the annual value of $13.0 million for FY2024, which is 106.56% up from last year.
- As of FY2024, Astria Therapeutics' Share-based Compensation stood at $13.0 million, which was up 106.56% from $6.3 million recorded in FY2023.
- Over the past 5 years, Astria Therapeutics' Share-based Compensation peaked at $13.0 million during FY2024, and registered a low of $1.4 million during FY2020.
- Over the past 3 years, Astria Therapeutics' median Share-based Compensation value was $6.3 million (recorded in 2023), while the average stood at $8.0 million.
- In the last 5 years, Astria Therapeutics' Share-based Compensation declined by 8.07% in 2020 and then spiked by 141.87% in 2021.
- Over the past 5 years, Astria Therapeutics' Share-based Compensation (Yearly) stood at $1.4 million in 2020, then spiked by 141.87% to $3.4 million in 2021, then soared by 35.46% to $4.6 million in 2022, then surged by 38.65% to $6.3 million in 2023, then soared by 106.56% to $13.0 million in 2024.